Despite substantial progress in the management of childhood acute myeloid leukemia (AML), only about 50% of patients are cured by intensive chemotherapy. The long-term results of clinical trials may reveal principles that can guide the development of future therapy. From 1980 to 2000, 251 ...
Immuno-Oncology continues to play a more relevant role in cancer treatment, and the advent of promising immunotherapies calls for novel approaches to clinical trials. Cell and Gene Therapies Working with living therapies presents new and unique challenges to the traditional clinical trial model. ...
Clinical trialsLymphomaHematologyThis chapter's fundamental tenet is that the conventional methodology used to evaluate new drugs is incongruent with clinical reality; in particular, the former frequently underestimates the complexity of the latter. I will point out that this situation is by no means ...
In a potential development for clinical trial translations to come, the U.S. Food and Drug Administration (FDA) authorized orphan drug designation (ODD) to Nkarta’s engineered natural killer (NK) cell therapy NKX101 for the treatment of acute myeloid leukemia (AML). AML i...
in that they are being evaluated in clinical trials and are not yet approved for use by regulatory authorities. Approval by regulatory authorities around the world, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is required to make our medicine ...
Clinical Trials Evaluating Lenvatinib Plus Everolimus in Advanced Renal Cell Carcinoma EP: 6.LITESPARK-005: Belzutifan in Previously Treated Advanced Clear Cell RCC EP: 7.Case 2: A 48-Year-Old Man with Renal Cell Carcinoma EP: 8.Adjuvant Immunotherapy in Renal Cell Carcinoma EP: 9.KE...
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials View More Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care View More Community Practice Connections™: Case Discussions in...
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials View More Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care View More Community Practice Connections™: Case Discussions in...
Expanding the repertoire of antigen targets for CAR-T is another viable approach. In this respect, universal anti-CD123 CAR-T (UCART123) therapy initiated by Cellectis (2017) was not as successful as the CD19 one. The first two patients treated in two clinical trials for AML and blastic ...
Patient-centric oncology CRO services Oncology and hematology studies dominate the clinical trial landscape, but the path to regulatory approval is complex and uncertain. And for the millions of patients each year facing a cancer diagnosis, the search for answers can’t wait. ...